ArticleOncology letters2019
SOX9 promotes epithelial-mesenchymal transition via the Hippo-YAP signaling pathway in gastric carcinoma cells.
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Advances in the study of the relationship between neurotransmitters and gastric cancer.World journal of gastroenterology · 2025Review
- Exploring kartogenin: advances in therapeutics and signaling mechanisms for musculoskeletal regeneration.Molecular biology reports · 2025Review
- Mechanobiological Strategies to Enhance Ovine (Animals : an open access journal from MDPI · 2024Article
- Cholinergic Mechanisms in Gastrointestinal Neoplasia.International journal of molecular sciences · 2024Review
- SRY-Box transcription factor 9 triggers YAP nuclear entry via direct interaction in tumors.Signal transduction and targeted therapy · 2024Article
- HuR (ELAVL1) StabilizesCancers · 2024Article
- Role of Sox9 in BPD and its effects on the Wnt/β-catenin pathway and AEC-II differentiation.Cell death discovery · 2024Article
- Use of iTRAQ-based quantitative proteomic identification of CHGA and UCHL1 correlated with lymph node metastasis in colorectal carcinoma.Journal of cellular and molecular medicine · 2023Article
- CRISPR-cas9 screening identified lethal genes enriched in Hippo kinase pathway and of predictive significance in primary low-grade glioma.Molecular medicine (Cambridge, Mass.) · 2023Article
- Rac1 promotes the reprogramming of glucose metabolism and the growth of colon cancer cells through upregulating SOX9.Cancer science · 2023Article
- Review
- Polyacetylene Isomers Isolated fromMolecules (Basel, Switzerland) · 2023Article
- Resveratrol inhibits TGF-β1-induced EMT in gastric cancer cells through Hippo-YAP signaling pathway.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Article
- The deadly cross-talk between Hippo pathway and epithelial-mesenchymal transition (EMT) in cancer.Molecular biology reports · 2022Review
- Article
- Mesenchymal-to-epithelial transition of osteoblasts induced by Fam20c knockout.Genes & genomics · 2022Article
- Epithelial-mesenchymal transition and its transcription factors.Bioscience reports · 2022Review
- The YAP/TAZ Signaling Pathway in the Tumor Microenvironment and Carcinogenesis: Current Knowledge and Therapeutic Promises.International journal of molecular sciences · 2021Review
- Subcellular localization of HMGB1 in human cholangiocarcinoma: correlation with tumor stage.Discover oncology · 2021Article
- Glycyrrhizin Attenuates Carcinogenesis by Inhibiting the Inflammatory Response in a Murine Model of Colorectal Cancer.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SRY-box 9 (SOX9) is overexpressed in a number of human tumors, including gastric cancer (GC). However, the function of SOX9 in the development of GC remains unknown. In the present study, SOX9 activated the Hippo-yes-associated protein (YAP) signaling pathway to enhance the epithelial-mesenchymal transition in GC cell lines. The results suggested that SOX9 knockdown inhibited invasion, proliferation and migration of GC cells. Furthermore, SOX9 silencing upregulated the expression of E-cadherin, an epithelial marker, and downregulated the expression of mesenchymal markers, including snail family transcriptional repressor 1, vimentin and N-cadherin. SOX9 overexpression increased the expression of the aforementioned markers. SOX9 significantly affected YAP phosphorylation and total YAP protein levels, suggesting that SOX9 is involved in the Hippo-YAP signaling pathway. The current study revealed that SOX9 may be involved in the pathogenesis of GC, and further elucidation of the pathways involved may support the development of novel therapeutic options for the treatment of GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.